Salofalk 500mg Tablets PBS Listed for Colitis and Crohn’s Disease

Salofalk 500mg tablets are now indicated in the treatment of acute episodes and maintenance of remission: – Mild to moderate ulcerative colitis – Crohn?s ileitis and colitis

PBS Listed, effective 1st August 2005 ? Authority Required (100 tablets + 5 repeats) for Colitis and Crohn?s disease where hypersensitivity to sulphonamides exists; Colitis and Crohn?s disease where intolerance to sulfasalazine exists.Crohn?s disease is estimated to affect approximately 30,000 people in Australia, and the most important therapeutic goal in this condition is the maintenance of remission; this is the disease state that many Crohn?s patients will spend the majority of their lives in.Salofalk is available in a convenient 500mg tablet which is well tolerated and offers the convenience of ingesting fewer tablets than other forms of mesalazine tablets. Please review Product Information before prescribing. Further information, samples and patient information on Salofalk can be requested from Orphan Australia on 1300 656 755.Salofalk is also available in granule and enema formulations. All Salofalk formulations, including tablets, are indicated for acute and maintenance treatment of ulcerative colitis of mild to moderate severity.For further information please contact Anne Hodgson, Business Manager – Gastroenterology on 1300 656 755